We are live on ! Find out more
GLUE icon

Monte Rosa Therapeutics
GLUE

105 hedge funds and large institutions have $276M invested in Monte Rosa Therapeutics in 2025 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 23 increasing their positions, 44 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more call options, than puts

Call options by funds: $413K | Put options by funds: $206K

5% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 21

1% more funds holding

Funds holding: 104 → 105 (+1)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

2.49% less ownership

Funds ownership: 99.26% → 96.77% (-2.5%)

35% less capital invested

Capital invested by funds: $423M → $276M (-$147M)

48% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 44

Holders
105
Holders Change
+1
Holders Change %
+0.96%
% of All Funds
1.41%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
22
Increased
23
Reduced
44
Closed
21
Calls
$413K
Puts
$206K
Net Calls
+$207K
Net Calls Change
-$1.84M

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$17.8M
2
PL
Parkwood LLC
Ohio
+$2.36M
3
ACA
Avoro Capital Advisors
New York
+$1.84M
4
RAM
Readystate Asset Management
Illinois
+$1.76M
5
Millennium Management
Millennium Management
New York
+$1.74M

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$11.2M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$5.36M
3
Citadel Advisors
Citadel Advisors
Florida
-$4.77M
4
Norges Bank
Norges Bank
Norway
-$3.09M
5
VPC
Vestal Point Capital
New York
-$2.95M
Name Holding Trade Value Shares
Change 		Change in
Stake
Wellington Management Group
26
Wellington Management Group
Massachusetts
$871K -$209K -34,010 -15%
TD Asset Management
27
TD Asset Management
Ontario, Canada
$798K -$294K -48,018 -22%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$762K -$37.8K -6,167 -4%
Renaissance Technologies
29
Renaissance Technologies
New York
$761K -$500K -81,600 -33%
IC
30
Ikarian Capital
Texas
$634K -$1.07M -175,000 -56%
N
31
Nuveen
North Carolina
$546K +$91K +14,837 +14%
Manulife (Manufacturers Life Insurance)
32
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$544K -$644 -105 -0.1%
American Century Companies
33
American Century Companies
Missouri
$466K +$144K +23,556 +31%
ECM
34
ExodusPoint Capital Management
New York
$447K +$591K +96,345 New
UBS Group
35
UBS Group
Switzerland
$425K +$197K +32,115 +54%
CC
36
Casdin Capital
New York
$399K – – –
RhumbLine Advisers
37
RhumbLine Advisers
Massachusetts
$289K +$2.75K +448 +0.7%
Susquehanna International Group
38
Susquehanna International Group
Pennsylvania
$247K +$201K +32,816 +160%
Verition Fund Management
39
Verition Fund Management
Connecticut
$240K +$317K +51,725 New
Qube Research & Technologies (QRT)
40
Qube Research & Technologies (QRT)
United Kingdom
$226K -$232K -37,847 -44%
Barclays
41
Barclays
United Kingdom
$214K -$150K -24,531 -35%
State of Wisconsin Investment Board
42
State of Wisconsin Investment Board
Wisconsin
$175K +$32.2K +5,253 +16%
BHCM
43
Brevan Howard Capital Management
Jersey
$174K +$230K +37,574 New
Invesco
44
Invesco
Georgia
$164K +$138K +22,499 +175%
BFM
45
Boothbay Fund Management
New York
$163K -$344K -56,122 -61%
AllianceBernstein
46
AllianceBernstein
Tennessee
$163K – – –
GCM
47
Graham Capital Management
Connecticut
$151K +$200K +32,586 New
Citigroup
48
Citigroup
New York
$144K -$84.4K -13,769 -31%
CC
49
Corton Capital
Ontario, Canada
$136K -$18.5K -3,018 -9%
Wells Fargo
50
Wells Fargo
California
$132K -$255K -41,607 -59%
1
2
3 4 5

GLUE Hedge Fund Activity: Q1 2025 in Review

105 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Monte Rosa Therapeutics (GLUE) for Q1 2025, worth a combined $276M — down 35% from $423M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new GLUE positions and 21 closed out — a net gain of 1 holder — while 23 added to existing stakes and 44 trimmed.

The largest buyer was BVF Inc, adding an estimated $17.8M. The largest seller was Morgan Stanley, cutting an estimated $11.2M.

  • 105 institutional investors held Monte Rosa Therapeutics (GLUE) as of Q1 2025, up from 104 in Q4 2024.
  • Funds reported $276M of Monte Rosa Therapeutics stock for Q1 2025, down 35% quarter-over-quarter.
  • 22 funds opened new Monte Rosa Therapeutics positions in Q1 2025 and 21 closed out, a net change of +1 holder.
  • The largest Monte Rosa Therapeutics buyer in Q1 2025 was BVF Inc, an estimated $17.8M added.
  • The largest Monte Rosa Therapeutics seller in Q1 2025 was Morgan Stanley, an estimated $11.2M sold.

Based on aggregated 13F filings for Q1 2025.